Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP‐NETs: A Review of Key Issues

por Anthony, Lowell B., O'Dorisio, Thomas M.
Publicado 2021

Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary

por Hendifar, Andrew E., Ramirez, Robert A., Anthony, Lowell B., Liu, Eric
Publicado 2019

Demographics and anthropometrics impact benefits of health intervention: data from the Reduce Obesity and Diabetes Project

por Ostrowski, L., Speiser, P. W., Accacha, S., Altshuler, L., Fennoy, I., Lowell, B., Rapaport, R., Rosenfeld, W., Shelov, S. P., Ten, S., Rosenbaum, M.
Publicado 2019

Global burden of neuroendocrine tumors and changing incidence in Kentucky

por Chauhan, Aman, Yu, Qian, Ray, Neha, Farooqui, Zainab, Huang, Bin, Durbin, Eric B., Tucker, Thomas, Evers, Mark, Arnold, Susanne, Anthony, Lowell B.
Publicado 2018

Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy

por Hilal, Talal, Nakazawa, Mary, Hodskins, Jacob, Villano, John L., Mathew, Aju, Goel, Guarav, Wagner, Lars, Arnold, Susanne M., DeSimone, Philip, Anthony, Lowell B., Hosein, Peter J.
Publicado 2017

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome

por Dillon, Joseph S., Kulke, Matthew H., Hörsch, Dieter, Anthony, Lowell B., Warner, Richard R. P., Bergsland, Emily, Welin, Staffan, O’Dorisio, Thomas M., Kunz, Pamela L., McKee, Chad, Lapuerta, Pablo, Banks, Phillip, Pavel, Marianne
Publicado 2020

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial

por Pavel, Marianne, Gross, David J, Benavent, Marta, Perros, Petros, Srirajaskanthan, Raj, Warner, Richard R P, Kulke, Matthew H, Anthony, Lowell B, Kunz, Pamela L, Hörsch, Dieter, Weickert, Martin O, Lapuerta, Pablo, Jiang, Wenjun, Kassler-Taub, Kenneth, Wason, Suman, Fleming, Rosanna, Fleming, Douglas, Garcia-Carbonero, Rocio
Publicado 2018

A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

por Mansfield, Aaron S., Hong, David S., Hann, Christine L., Farago, Anna F., Beltran, Himisha, Waqar, Saiama N., Hendifar, Andrew E., Anthony, Lowell B., Taylor, Matthew H., Bryce, Alan H., Tagawa, Scott T., Lewis, Karl, Niu, Jiaxin, Chung, Christine H., Cleary, James M., Rossi, Michael, Ludwig, Carrianne, Valenzuela, Ricardo, Luo, Yan, Aggarwal, Rahul
Publicado 2021